EUVIMEDEUVIMED entdecken
Crossref

Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Meiling Chen, Yuanzhong Chen, Shaoyuan Wang, Feng'e Yang, Jing Zheng, Danhui Fu, Jia Lin, Xiaofan Li, Nainong Li

Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · e1218-e1228.e3

DOI: 10.1016/j.clml.2026.07.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Meiling Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, F…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Azacitidine, fms-Like Tyrosine Kinase 3, Sulfonamides. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Gilteritinib (GIL)-based venetoclax regimens are active in relapsed or refractory (R/R) fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), but real-world delivery after prior targeted therapy remains challenging. PATIENTS AND METHODS: Adults with FLT3-mutated AML treated with GIL-based therapy from May 2021 to May 2025 were retrospectively reviewed. The analysis focused on patients with active R/R disease who received GIL, venetoclax (VEN), and azacitidine (AZA); patients who received single-agent GIL as post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) maintenance without active leukemia were not the subject of this study and were excluded. The primary endpoint was modified composite remission (mCRc) within 2 cycles. RESULTS: Thirty-eight patients received GIL/VEN/AZA for active R/R disease. Prior FLT3-inhibitor and VEN exposure were present in 63.2% and 28.9%. Early day 14-21 marrow clearance/aplasia occurred in 63.2%, and VEN shortening/interruption in 78.9%. mCRc occurred in 60.5% (95% confidence interval [CI], 43.4-76.0). Among evaluable responders, multiparameter flow-cytometry measurable residual disease (MRD) negativity and FLT3 molecular MRD negativity occurred in 66.7% and 72.2%. Median overall survival was 11.2 months. Prior FLT3-inhibitor exposure was not associated with inferior outcome, whereas RAS/mitogen-activated protein kinase (RAS/MAPK)-pathway co-mutation was associated with lower mCRc and shorter survival. Grade 3 or higher infection occurred in 47.4%, and 60-day mortality was 5.3%. Paired failure profiling showed FLT3-persistent and FLT3-loss patterns. CONCLUSION: GIL/VEN/AZA was feasible in selected heavily pretreated R/R FLT3-mutated AML with early marrow-guided dose adaptation. Molecular context and repeat profiling may guide subsequent therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAzacitidinefms-Like Tyrosine Kinase 3SulfonamidesBridged Bicyclo Compounds, HeterocyclicAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsPyrazinesHumansFemaleMaleMiddle AgedAgedMutationRetrospective StudiesAdult

Stichwörter der Autor:innen

Allogeneic stem-cell transplantationClonal evolutionHypomethylating agentMeasurable residual diseaseTriplet therapy

Substanzen

Azacitidinefms-Like Tyrosine Kinase 3gilteritinibSulfonamidesBridged Bicyclo Compounds, HeterocyclicAniline CompoundsvenetoclaxPyrazinesFLT3 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Translational Medicine Center on Hematology, Fuj…
  • Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • Translational Medicine Center on Hematology, Fujian Medical University, Fuzhou, Fujian, China; Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematolo…

Zitieren

APA

Chen, M., Chen, Y., Wang, S., Yang, F., Zheng, J., Fu, D., Lin, J., Li, X., & Li, N. (2026). Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia, 26(10), e1218-e1228.e3. https://doi.org/10.1016/j.clml.2026.07.015

Vancouver

Chen M, Chen Y, Wang S, Yang F, Zheng J, Fu D, et al. Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):e1218-e1228.e3. doi:10.1016/j.clml.2026.07.015

BibTeX
@article{Chen2026,
  author = {Chen, Meiling and Chen, Yuanzhong and Wang, Shaoyuan and Yang, Feng'e and Zheng, Jing and Fu, Danhui and Lin, Jia and Li, Xiaofan and Li, Nainong},
  title = {Real-World Delivery, Dose Adaptation, and Molecular Monitoring of Gilteritinib, Venetoclax, and Azacitidine in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {10},
  pages = {e1218--e1228.e3},
  doi = {10.1016/j.clml.2026.07.015}
}
Kostenlos starten →